Web-based cardiology software developer Perminova has added Gail Naughton, a veteran in business, finance, biomedicine and academia, to its board of advisers.
Currently chief executive officer and chairman of Histogen Inc., a regenerative medicine company founded by her in 2007, Naughton also serves as a director for C.R. Bard Inc., which, in part, develops diagnostic devices for treating cardiac arrhythmias. Naughton is a former dean of the College of Business Administration at San Diego State University, a post that made her the first female biotechnology entrepreneur to lead a major U.S. business school.
Her background in biotech goes back to her co-founding of Advanced Tissue Sciences in 1986 and holding the position of assistant professor of research at New York University Medical Center before that.
Holder of nearly 100 U.S. and foreign patents, Naughton earned her bachelor’s degree from St. Francis College in Brooklyn, N.Y., and both a master’s degree in histology and doctorate in hematology from New York University Medical Center. She also holds an M.B.A. in executive management from the Anderson School at UCLA.